Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer.
Breast cancer is the second leading cause of cancer death in women, affecting 1.7 million patients every year worldwide. As a result of its heterogeneous nature, the genetic profile and associated clinical feature varies greatly among different breast cancer subtypes. With the advancement of molecular biology, our understanding of breast cancer has improved greatly in recent years. In this review, we examine different types of breast cancer and summarize their clinical features, current treatment schemes, and potential drug resistance profiles in response to treatments. We believe that the understanding of the molecular mechanisms of each treatment and subsequent drug resistance development will eventually lead to the discovery of more effective and efficient second-line therapeutics.
Department of Mechanical Engineering, Temple University, Philadelphia, PA.
Yuan
Y
Tang
Hematology and Medical Oncology, Lankenau Medical Center, Wynnewood, PA.
Yue
Y
Wang
Department of Mechanical Engineering, Temple University, Philadelphia, PA.
Mohammad F
MF
Kiani
Department of Mechanical Engineering, Temple University, Philadelphia, PA; Department of Biomedical Engineering, Widener University, Chester, PA. Electronic address: bwang@widener.edu.
Bin
B
Wang
D018435:ATP Binding Cassette Transporter, Subfamily B / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000145:classification* / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D016896:Treatment Outcome
D018435:ATP Binding Cassette Transporter, Subfamily B; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C513055:ABCB1 protein, human; C508053:ERBB2 protein, human
Clinical trials; Endocrine therapy; Pathways; Treatment strategies; Triple-negative breast cancer